Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors - Bergsma, H; van Lom, K; Raaijmakers, M H (Journal of Nuclear Medicine, 2018)
et al.